Disclosed are compounds of Formula G1: ##STR00001##
where R.sup.G3. R.sup.d1 to R.sup.d4, n, m, p, W, X, Y, and Z are defined herein, which compounds are antagonists of A.sub.2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A.sub.2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

The subject matter disclosed herein generally relates to modulators of Clavibacter michiganensis subsp. michiganensis, derivatives thereof, formulations thereof, coated seeds, and methods of using such compounds to treat diseases such as bacterial canker in plants.

The subject matter disclosed herein generally relates to modulators of Clavibacter michiganensis subsp. michiganensis, derivatives thereof, formulations thereof, coated seeds, and methods of using such compounds to treat diseases such as bacterial canker in plants.

The subject matter disclosed herein generally relates to modulators of Clavibacter michiganensis subsp. michiganensis, derivatives thereof, formulations thereof, coated seeds, and methods of using such compounds to treat diseases such as bacterial canker in plants.

The present invention relates to herbicidally-active pyridino-/pyrimidino-pyrazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.

The present invention relates to herbicidally-active pyridino-/pyrimidino-pyrazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.

Disclosed are polycationic polymers. The polycationic polymers can include a plurality of positively charged centers, each of which is formed by condensation of cyclic bis-electrophile (e.g., a 9-thia/aza/selenabicyclo[3.3.1]nonyl electrophile) with a nucleophile. The resulting polycationic polymers can efficiently bind nucleic acids. The polycations can also exhibit properties of cytotoxicity and DNA transfection with interesting structure-activity characteristics.

The invention provides methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.

The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

Disclosed are compounds of Formula G1 (structurally represented): where RG3 Rd1 to Rd4, n, m, p, W, X, Y, and Z are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. ##STR00001##